Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

Diabetes

Volumn 51, Issue 2, 2002, Pages 424-429

  Juhl, Claus B ^a   Hollingdal, Malene ^a   Sturis, Jeppe ^b   Jakobsen, Grethe ^b   Agersø, Henrik ^b   Veldhuis, Johannes ^c   Pørksen, Niels ^a   Schmitz, Ole ^a,d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF VIRGINIA   (United States)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLGLUCOSE; C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIRAGLUTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; MALE; MEAL; MEASUREMENT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH EMPTYING; TREATMENT PLANNING;

EID: 0036066641     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.2.424     Document Type: Article

References (35)

1. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
2. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus
3. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
4. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
5. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
6. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
7. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM
8. Short-term treatment with GLP-1 increases pulsatile insulin secretion in type II diabetes with no effect on orderliness
9. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance
10. Pharmacokinetic profile of the long acting GLP-1 derivative NN2211 in healthy male subjects
11. Long-acting GLP-1 derivate NN2211 markedly attenuates diabetes development in the male Zucker diabetic fatty rats
12. Pulsatile insulin secretion accounts for 70% of total insulin secretion during fasting
13. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients
14. Prehepatic insulin production in man: Kinetic analysis using peripheral connecting peptide behavior
15. Estimation of insulin secretion rates from C-peptide levels: Comparison of individual and standard kinetic parameters for C-peptide clearance
16. The pituitary gland secretes in bursts: Appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations
17. In humans at least 75% of insulin secretion arises from punctuated secretory bursts
18. Approximate entropy as a measure of system complexity
19. Hormone pulsatility discrimination via coarse and short time-sampling
20. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gult
21. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
22. Role of glucagon in the pathogenesis of diabetes: The status of the controversy
23. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: The Hoorn Study
24. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
25. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
26. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
27. Glucagon-like peptide-1 infusion must be maintained for 24 hours/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment
28. Gastric emptying: Comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer assessment techniques
29. Pulsatile insulin has greater hypoglycemic effect than continuous delivery
30. Efficacy of pulsatile versus continuous insulin administration on hepatic glucose production and glucose utilization in type I diabetic humans
31. Glucose entrainment of highfrequency plasma insulin oscillations in control and type 2 diabetic subjects
32. Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes
33. Acute and short-term administration of a sulphonylurea (Gliclazide) increases pulsatile insulin secretion in type 2 diabetes
34. Glucagon-like peotide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance